Targeted Silencing of IFIH1/MDA5 with a CD71 Centyrin–siRNA Conjugate for the Treatment of Type 1 Diabetes

• IFIH1/MDA5 is a genetically and mechanistically validated driver of Type 1 Diabetes, linking innate antiviral sensing to aberrant interferon signaling and autoimmune disease.
• Enabling cell-selective delivery and potent silencing of IFIH1/MDA5 using CD71- targeted Centyrin–siRNA conjugates, providing a strategy to modulate diseaserelevant innate immune signaling
• Demonstrating pharmacodynamic and disease-modifying activity in pre-clinical studies, supporting continued development of targeted RNAi as a potential therapeutic approach for Type 1 Diabetes

New Data